Home » Topics » BioWorld Science

BioWorld Science
RSS

DZD-4205 demonstrates efficacy in phase I/II JACKPOT8 study in PTCL

Dec. 21, 2020

Olinvacimab plus pembrolizumab shows clinical benefit in phase Ib study in mTNBC

Dec. 21, 2020

Phase II study of BN-Brachyury in chordoma shows signs of clinical activity

Dec. 21, 2020

Interim analysis update on remestemcel-L study in COVID-19 ARDS

Dec. 21, 2020

Metacrine reports phase I data on FXR agonist MET-642

Dec. 21, 2020

FDA clears IND for AlloVir's ALVR-106 to treat severe respiratory viral infections

Dec. 18, 2020

Shionogi initiates phase I/II study in Japan with COVID-19 vaccine candidate

Dec. 18, 2020

Albireo starts phase III trial of odevixibat in Alagille syndrome

Dec. 18, 2020

First-in-human data presented for AB-928 with or without IPI-549 in patients with cancer

Dec. 18, 2020

EDP-1503 plus pembrolizumab safe and well-tolerated in TNBC patients

Dec. 18, 2020

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...